Advertisement

Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Janakiram on Future Targets and Strategies for CAR T-cell Therapy in Myeloma

November 22nd 2022

Murali Janakiram, MD, MS, discusses future targets and research strategies for CAR T-cell therapy in multiple myeloma.

Belantamab Mafodotin to Be Withdrawn From US Market for Relapsed/Refractory Myeloma

November 22nd 2022

GlaxoSmithKline plc has initiated the process to withdraw the United States marketing authorization for belantamab mafodotin-blmf for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 4 prior therapies.

Standard Induction Evolves in Transplant-Eligible and -Ineligible Multiple Myeloma

November 16th 2022

Shambavi Richard, MD, discussed key studies that continue to shape the SOC in both the transplant-eligible and -ineligible populations, the role of transplant in the space, and unmet needs that remain for older and frail patients.

Belantamab Mafodotin Fails to Meet PFS End Point in Relapsed/Refractory Multiple Myeloma

November 7th 2022

Belantamab mafodotin-blmf did not generate a progression-free survival benefit vs the combination of pomalidomide plus low-dose dexamethasone, failing to meet the primary end point of the phase 3 DREAMM-3 trial.

Putting Culturally Competent Care into Practice

November 4th 2022

Joseph Mikhael, MD, and Craig Cole, MD, close the program by sharing examples of times culturally competent care was paramount to the treatment of their patients.

FDA Grants Breakthrough Therapy Designation to Elranatamab for Relapsed/Refractory Multiple Myeloma

November 3rd 2022

The FDA has granted a breakthrough therapy designation to elranatamab for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Voorhees on the Utilization of Proteasome Inhibitors for Newly Diagnosed Multiple Myeloma

November 2nd 2022

Peter Voorhees, MD, discusses developments in the efficacy and application of proteasome inhibitors for patients with newly diagnosed multiple myeloma.

BCMA and CD3 T-cell–Engaging Bispecific Antibody Shows Promise in R/R Multiple Myeloma

November 1st 2022

ABBV-383 was effective and well tolerated at all administered doses in patients with relapsed/refractory multiple myeloma, according to safety and efficacy results from an ongoing first-in-human, phase 1 dose-escalation/-expansion study.

Dr. Susanibar-Adaniya on the Evolution of Combination Therapies in Multiple Myeloma

October 31st 2022

Sandra P. Susanibar-Adaniya, MD, discusses how advancements in triplet therapy have shifted the treatment paradigm for patients with newly diagnosed, transplant-ineligible multiple myeloma.

Disparities in Multiple Myeloma Care: The Path Toward Health Equity

October 28th 2022

Expert panelists share their closing thoughts on the path to improve health equity in multiple myeloma management for racial and ethnic minority groups.

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

Drs Mikhael and Cole discuss ways to help reduce disparities in myeloma by delivering culturally relevant care and highlight the importance of implementing shared decision-making, creating a well-informed multidisciplinary staff, and meeting patients where they are.

Advice on Delivering Culturally Competent Care for Community Physicians

October 27th 2022

Craig Cole, MD, shares advice for community physicians on providing culturally competent care to patients with multiple myeloma that embraces their beliefs, spiritualities, and ethnicities.

The Barriers to Quality Care for Black American Patients with Multiple Myeloma

October 27th 2022

A key opinion leader lists the factors that affect access to quality care for Black Americans with multiple myeloma.

Melphalan Flufenamide Plus Daratumumab Elicits PFS Benefit in Relapsed/Refractory Myeloma

October 26th 2022

The combination of melphalan flufenamide and daratumumab plus hyaluronidase-fihj and dexamethasone improved progression-free survival over daratumumab and dexamethasone alone in select patients with relapsed/refractory multiple myeloma.

Dr. Garfall of the FDA Approval of Teclistamab in Relapsed/Refractory Multiple Myeloma

October 25th 2022

Alfred L. Garfall, MD, discusses the significance of the FDA approval of teclistamab-cqyv in relapsed/refractory multiple myeloma and how this agent might fit into the treatment paradigm going forward.

FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma

October 25th 2022

The FDA has granted accelerated approval to teclistamab-cqyv (Tecvayli) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Dr. Varga on Current Clinical Trials for Patients with Relapsed/Refractory Multiple Myeloma

October 24th 2022

Cindy Varga, MD, discusses several exciting clinical trials at the Levine Cancer Institute for patients with relapsed/refractory multiple myeloma with acquired resistance to BCMA-directed therapy.

Addressing Healthcare Provider Bias in Multiple Myeloma Management

October 21st 2022

Joint consideration for physician bias in the management of multiple myeloma and how it can be addressed while treating patients belonging to racial and ethnic minority groups.

Improving Access to Clinical Trials in Multiple Myeloma

October 21st 2022

Centering discussion clinical trials in multiple myeloma, panelists review how to improve access to these studies for racial and ethnic minority groups.

Multiple Myeloma Clinical Trial Enrollment in the Black American Population

October 20th 2022

An expert discusses the stigmas behind clinical trials and the shockingly low rate of enrollment by Black Americans with multiple myeloma.

Advertisement
Advertisement